Summary.-One hundred and nineteen unselected and similarly treated patients with Ph1-positive chronic granulocytic leukaemia (CGL) had the precise nature of their chromosome rearrangements producing the Ph1 studied to determine whether this had any clinical relevance. Eighteen (15°,) did not have the usual 9/22 translocation and these, by life-table analysis, had a significantly shorter benign phase of their disease than the others (P<0.01). It further appeared that possession of a nonstandard Ph' was related to age, in that whereas only 24 patients were over 60 at diagnosis, 9 (33%) had a non-9/22 translocation (P<0.01).
(CGL) is associated with possession of the Philadelphia chromosome (Phl, a characteristically altered Number 22) and is clinically typified as a biphasic disease with a benign phase of about 3 years followed by malignant transformation and subsequent survival of about 3 months.
The commonest chromosome rearrangement to produce Phl is a 9/22 translocation (Rowley, 1973) but subsequent authors have shown that in a minority of patients other rearrangements can produce similar appearances in Chromosome 22 (IHayata et al., 1973; Gahrton et al., 1974) . Although such non-standard Phls are not thought relevant to the clinical course of the disease by Sandberg (1980) we report here a large series which appears to contradict this belief.
PATIENTS AND METHODS
The patients were collected over 5 years, and all referred cases of Phl-positive CGL which were successfully banded were included in the series. So-called Phl-negative CGL, and those appearing as Phl-positive acute leukaemia were excluded. Ages ranged from 14 to 76 years with a mean of 46-5. There were 59 males and 60 females. (Seabright, 1971) .
Cell suspensions from blood samples or spleens w%ere incubated in 10 ml of culture medium (3 parts foetal calf serum: 7 parts TC 199) for 64 h, and for a further 6 h with 01 jug/ml colcemid. Harvesting and slide preparation w%ere the same as with marrow samples. (23, 47 and 69) have been included in a previous publication (Potter et al., 1975) . Two Phi cases (20%) showing deletion of Chromosome 22 were also found, and included with the non-standard Phl translocations in this study. Mean age at diagnosis of the non-standard Phi cases was 54 3 years, compared with 44-9 years for cases with a 9/22 translocation.
By life-table analysis the duration of the benign phase was significantly shorter for the non-standard PhI patients (median 20 months) than for those with a standard Phi (median 43 months) (P < 0. 01). It also appeared that non-standard Ph1 translocations were associated with older patients as, of 24 patients over 60 at diagnosis, 9 (37.50/%) had a non-standard Phl compared to only 11 (11-6%) of those <60 (P<001, x2). As those aged 60 and over at diagnosis had a significantly shorter benign phase than the rest, irrespective of chromosome status (median again 20 months vs 43 months, P < 0-01), the question arose whether a non-standard Phl simply occurred more frequently in older patients who had a worse prognosis or whether it had any independent prognostic value. An attempt to answer this was made by comparing the duration of the benign phase in 4 subgroups of patients; (A) 84 under 60 at diagnosis with a typical Ph 1, (B) 15 x 60 + atdiagnosiswith a typical Ph', (C) 11 under 60 at diagnosis with a non-standard Phl, and (D) 7 x 60 + at diagnosis with a non-standard Phl. From this it was seen that patients in Groups B, C and D all had a significantly shorter benign phase than patients in Group A, but did not appear to differ from each other. The difference between Group A and Groups B and C is shown graphically in the figure. Group D had a median duration of benign phase of 19 months, and did not appear different in any way from Group B; in other words all those 60 and over had a poor prognosis irrespective of the Phl translocation. The presence of nonstandard Ph' under 60, however, appeared to be associated with a more rapidly evolving disease a prognostic effect presumably masked by age.
DISCUSSION
The nature and significance of unusual Phl translocations have recently been the subject of a multicentre review (Sandberg, 1980) which concluded that the survival of patients with such translocations did not differ significantly from that of patients with the standard 9/22 translocation. Our data seem to contradict this for, although we used the duration of the benign phase rather than survival as our prognostic yardstick, the clear impression is given that non-standard Phl chromosomes tend to be associatedl with a worse prognosis. They also seem associated with older patients who, in this series, had a worse prognosis irrespective of karyotype, so age may have a stronger influence on outlook.
Our methods might seem open to criticism, in that it could be argued that the duration of the benign phase is hard to measure and depends on the bias of the managing physician deciding when transformation has occurred. This we acknowledge, but would emphasize that such bias would affect all groups of patients equally (and thus be self-cancelling) and that while it is hard to define in words, the event of transformation is frequently obvious in clinical practice. The benign phase duration seems totally unaffected by variations in current conservative treatment.
It is possible that, within the cytogenetic heterogeneity of the non-standard Ph1s we have described, there exists a better defined subgroup which is perhaps responsible for the observed effect on prognosis of the group as a whole. Numbers are too small to be other than suggestive, but it may be that the complex translocations arise more frequently in older patients than do simple translocations involving a chromosome other than a 9. Our data would support this, but much greater numbers will be needed to answer the question with confidence. Meanwhile, any patient with a non-standard Phl should be regarded as potentially having a worse outlook than those with an uncomplicated 9/22 translocation.
